Taxotere docetaxel data

Results from four Phase II studies with 315 evaluable advanced ovarian cancer patients showed an overall response rate of 30 percent. Among the 81 patients in two studies who were considered to have the most refractory disease, the response rate was 20 percent.

Results were reported at a symposium sponsored by RPR in Prague, the Czech Republic. ...